Literature DB >> 34285489

Aβ Influx into the Blood Evoked by Different Blood Aβ Removal Systems: A Potential Therapy for Alzheimer's Disease.

Nobuya Kitaguchi1, Kazunori Kawaguchi1, Miwa Sakata1, Hiroki Aoki1, Kazunori Yamazaki1, Megumi Kaneko1, Jun Kinomura1, Masao Kato2, Midori Hasegawa2, Nobuo Suzuki3, Masao Mizuno4, Yukio Yuzawa2.   

Abstract

PURPOSE: Amyloid-β (Aβ) is a brain protein that causes Alzheimer's disease. We have revealed that extracorporeal blood Aβ-removal systems evoked a large Aβ influx into the blood. This study investigated the system that is more effective in evoking Aβ influx.
METHODS: Aβ removal activities were compared between hexadecyl-alkylated cellulose beads (HexDC) and fragments of polysulfone hollow fibers (PSf-HFs) in mini-columns to eliminate the filtration effect. Then, adsorptive filtration systems were adapted for PSf hemodialyzers to enhance Aβ adsorption on micropores in the wall of hollow fibers. Plasma Aβ concentrations of patients with renal failure were analyzed during treatment with PSf hemodialyzers alone for 8 h or tandemly connected HexDC and PSf hemodialyzers for 4 h.
RESULTS: In the in vitro study, Aβ removal efficiency for HexDC was approximately 100% during the 60 min treatment, whereas the removal efficiency for PSf-HF fragments gradually decreased. However, PSf hemodialyzer in adsorptive filtration systems removed Aβs comparably or more than HexDC. Aβ influx into the blood increases time-dependently. Concomitant use of HexDC and PSf hemodialyzer evoked a larger Aβ1-40 influx than that of PSf hemodialyzer alone. However, Aβ1-42 influx by PSf hemodialyzer alone was similar to or a little larger than influx by the combined system. Both systems evoked almost doubled Aβ influx than estimated Aβs existing in the normal brain during the 4 h treatment.
CONCLUSION: PSf hemodialyzer alone for a longer period and concomitant use of HexDC and PSf hemodialyzer for a shorter time effectively evoked a larger Aβ influx. To evoke Aβ1-42 influx, PSf hemodialyzer alone was effective enough. These findings of devices and treatment time may lead to optimal clinical settings for therapy and prevention of Alzheimer's disease.
© 2021 Kitaguchi et al.

Entities:  

Keywords:  3D printer; HexDC; amyloid; blood purification; extracorporeal system; polysulfone hemodialyzer

Year:  2021        PMID: 34285489      PMCID: PMC8286129          DOI: 10.2147/NDT.S317104

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


  27 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Potential therapeutic system for Alzheimer's disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients.

Authors:  Masao Kato; Kazunori Kawaguchi; Sigeru Nakai; Kazutaka Murakami; Hideo Hori; Atsushi Ohashi; Yoshiyuki Hiki; Shinji Ito; Yasunobu Shimano; Nobuo Suzuki; Satoshi Sugiyama; Hiroshi Ogawa; Hiroko Kusimoto; Tatsuro Mutoh; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Neural Transm (Vienna)       Date:  2012-06-15       Impact factor: 3.575

Review 3.  Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer's Disease.

Authors:  Kejing Lao; Ruisan Zhang; Jing Luan; Yuelin Zhang; Xingchun Gou
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

4.  Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model.

Authors:  Wang-Sheng Jin; Lin-Lin Shen; Xian-Le Bu; Wei-Wei Zhang; Si-Han Chen; Zhi-Lin Huang; Jia-Xiang Xiong; Chang-Yue Gao; Zhifang Dong; Ya-Ni He; Zhi-An Hu; Hua-Dong Zhou; Weihong Song; Xin-Fu Zhou; Yi-Zheng Wang; Yan-Jiang Wang
Journal:  Acta Neuropathol       Date:  2017-05-05       Impact factor: 17.088

5.  Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer's Disease by Removal of Blood Amyloid.

Authors:  Kazuyoshi Sakai; Takao Senda; Ryuji Hata; Makoto Kuroda; Midori Hasegawa; Masao Kato; Masato Abe; Kazunori Kawaguchi; Shigeru Nakai; Yoshiyuki Hiki; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

6.  Adsorptive filtration systems for effective removal of blood amyloid β: a potential therapy for Alzheimer's disease.

Authors:  Nobuya Kitaguchi; Kazunori Kawaguchi; Kazunori Yamazaki; Hiroshi Kawachi; Miwa Sakata; Megumi Kaneko; Masao Kato; Kazuyoshi Sakai; Norimi Ohashi; Midori Hasegawa; Yoshiyuki Hiki; Yukio Yuzawa
Journal:  J Artif Organs       Date:  2017-12-11       Impact factor: 1.731

7.  Toward the treatment for Alzheimer's disease: adsorption is primary mechanism of removing amyloid β protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate.

Authors:  Kazunori Kawaguchi; Akira Saigusa; Shinji Yamada; Takehiro Gotoh; Shigeru Nakai; Yoshiyuki Hiki; Midori Hasegawa; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Artif Organs       Date:  2015-12-19       Impact factor: 1.731

8.  Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

Authors:  Niki S Schoonenboom; Cees Mulder; Gerard J Van Kamp; Sangita P Mehta; Philip Scheltens; Marinus A Blankenstein; Pankaj D Mehta
Journal:  Ann Neurol       Date:  2005-07       Impact factor: 10.422

9.  Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.

Authors:  Jae-Eun Kang; Miranda M Lim; Randall J Bateman; James J Lee; Liam P Smyth; John R Cirrito; Nobuhiro Fujiki; Seiji Nishino; David M Holtzman
Journal:  Science       Date:  2009-09-24       Impact factor: 47.728

10.  Editorial: A Is for Amyloid.

Authors:  D J Selkoe
Journal:  J Prev Alzheimers Dis       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.